




Painless Monitoring for Personalized Prevention

Index

Objective	P.1
Team & Traction	P.2
Technology	P.3
Detection	P.4
Prediction	P.5
Go-to-Market	P.6
Commercial Plan	P.7
Company Structure	P.8
Competitive Landscape	P.9
Stage of Development	P.10
Financial Position	P.12
Financial Projections	P.13



Objective

Non Communicable Diseases
are the largest cause of death



80%
are preventable

- | | |
|-----------------------|------------------|
| Cardiovascular 19 M | Kidney 1.2 M |
| Cancers 10 M | Digestive 1.1 M |
| Respiratory 4.1 M | Neurological 1 M |
| Diabetes 2 M | Mental .8 M |
| Liver Cirrhosis 1.3 M | Other 2.3 M |




“Empower healthier lives through
effortless prevention”

Extend 1 million lives by 10 healthy years

Wider awareness and regular monitoring

Simple & Accesible
30 seconds
Painless
Proven

Effective Incentives
Personalized
Prediction
Advice



Glucose



Heart Rate



SpO2



Blood Pressure



HRV · Arterial Compliance · Vascular Aging · Perfusion Index · Respiratory Rate

Team & Traction



MS Mayra Mora
MSc - Arts et Métiers
Technology Director



Antonio García
PhD - UC.Berkeley
Science Director



MS Victoria Merino
MSE - U.Pennsylvania
Research Director



Fernando Gomez
Entrepreneur
Executive Director



Felix Agakov
PhD - U.Edinburgh
Artificial Intelligence



Adriana Monroy
MD/PhD - UNAM/UT
Clinical Research



Lorena de la Maza
MD - UNAM/Harvard Med
Medical Strategy



Luis Gomez
JD - Harvard Law
Corporate Affairs



Global Finalist
2022
4^o/15,000



President Claudia Sheinbaum · Support from the Mexican Government (SECTEI / SEDESA)

5 Institutional Collaborations



GOBIERNO DE LA
CIUDAD DE MÉXICO



DR. EDUARDO LICEAGA




\$4.8 M raised
Patent Pending
4 R&D Grants
TRL 5/6

4 Iterations
4 Clinical Trials
3,700+ patients
180u requested

Technology


Near Infrared Spectroscopy · Quantum Light Rotation

Molecular Vibrational Absorption (NIR)





Electronic Absorption (Visible)

Right Rotation (Dextrorotatory)




Left Rotation (Levorotatory)


Photoplethysmography




Spectral Footprint



Processed SF



Correlated SF



Detection

Multi-metric
Competitors

Apple Watch
2 ●

Galaxy Watch
3 ●

Omron H.Guide
2 ●


Withings
1 ●

iHealth
1 ●

BodiMetrics
3 ●

Fully Non Invasive
Integrated Biomarker Landscape

● **Viit Health (4 biomarkers) - Our optical components allow for a high quality PPG signal**



Derived Markers
Improve Detection - New Correlations

HR Variability · Vascular Aging
Respiratory Rate · Perfusion Index
Arterial Compliance

Integrated Methodology

- A** - Preparatory ML (DSP)
- B** - Classical ML (GPR, etc)
- C** - Deep Learning (RNN, etc)

Ex. MAE <3 BPM *

<1% *

<5 mmHg *

±15 mg/dl *

Final Predictive Measurement

* Expected Results cannot be guaranteed · 1) Results obtained for normal BG levels (75 - 114 mg/dl) in previous Clinical Studies and validated according to class prediction (75-83, 84-93, 94-104, 105-114 mg/dl)

Prediction

**Glucose**

**Heart Rate**

**SpO2**

**Blood Pressure**

HRV · Arterial Compliance · Vascular Aging · Perfusion Index · Respiratory Rate

viit health

PP0087-1

General

Anthropometric

Vitals

Body Composition

Blood Chemistry

Variable	Result	Unidad	Instrument	Error
Height	160	CM	Cinta Métrica	0%
Weight	95	kg	InBody	TBD
Waist (C)	103.5	CM	Cinta Métrica	0%
Hip (C)	103	CM	Cinta Métrica	0%
Neck (C)	45.5	CM	Cinta Métrica	0%
Finger (C)	12 Y	CM	Cinta Métrica	0%

Sparse Parametric
Non Parametric
Temporal Embeddings
(Risk Prediction)

Optical novel predictors

Prediction before damage

i.e.

Hypertension

(consistently high BP)

Coronary Artery Disease (CAD)

(poor VA & PI, high BP, poor AC)

Ventricular Hypertrophy

(high BP & HR, poor VA)

Type 2 Diabetes

(consistently high BG, odd BP & AC)

Asthma


(High HR, low PI & SpO2)

1 + **27** conditions

Hypotension
Atrial Fibrillation
Tachycardia
Bradycardia
Heart Failure (CHF)
Arteriosclerosis
Peripheral Artery Disease (PAD)
Ischemic Heart Disease
Orthostatic Hypotension
Hypoglycemia
Metabolic Syndrome
Insulin Resistance
C. Obstructive Pulmonary Disease (COPD)
Pulmonary Hypertension
Anemia
Atherosclerosis
Autonomic Dysfunction
Dehydration
Overtraining Syndrome
Polycystic Ovary Syndrome (PCOS)
Non-Alcoholic Fatty Liver Disease (NAFLD)
Gestational Diabetes (...)


2 + **19** complications

Diabetic Retinopathy
Stroke
Transient Ischemic Attacks (TIAs)
Sudden Cardiac Arrest
Heart Attack (Myocardial Infarction)
Aneurysm
Blood Clots
Chronic Kidney Disease (CKD)
Preeclampsia
Pulmonary Embolism
Respiratory Failure
Pulmonary Edema
Deep Vein Thrombosis
Critical Limb Ischemia
Cognitive Decline
Dementia
Multi-Organ Dysfunction Risk (s. inflammation)
Peripheral Neuropathy
Shock (Hypovolemic or Cardiogenic)



92 Wellness Score

NCD Risk Prediction (5 yrs)



Go-to-Market

Targeted Personalized Prevention

US · Mexico · Canada · LATAM



Public Health, Prevention
& Personalized Medicine
Market


\$780 B

NCD Economic Burden - 2030

\$47 T

WHO · CDC · Global Wellness Institute · WEF

Customer Segments Risk & Organization Structure



Special Attention

Underserved Communities




Women's Health Clinic

Cost Reduction


97% Less Time

95% Less Analysis Cost

Revenue Increase



5,000 Patients



Preeclampsia	4%
Diabetes	20%
Hypertension	18%



Sofia Alvarez

Woman · 28
sofia@viit.health

Wellness Score **89**

March 25 - 2024

Results

History



Glucose

86

BPM

HR

99

SpO2

SpO2

112

Systolic

Blood Pressure

65

Diastolic

36

Celsius

Temperature



Sofia, your results indicate that you keep improving. Remember to do your anaerobic exercises to strengthen your circulatory system!

Commercial Plan

* Forward Looking Projections cannot be guaranteed

\$350
Device Cost

\$200-\$500
Mo. Org Subscription

\$10-\$20
Mo. Individual Subscription

Validation

Growth

Maturity

Targeted Personalized Prevention
(B2B/B2B2C)

Individual Prevention
(B2C)

Treatment
(B2B/B2C)

Market Activation

Expansion

Underserved Population
Focus on Women

Women
Elders
Children

At Risk / Wellness Conscious
Use-at-Home Telemedicine

Hospitals / MDs / Patients
Diagnosis
Treatment

Units: 200 - 550
Revenue: \$3M *
2026-27 (MX)

Units: 15K
Revenue: \$13M *
2028 (US)

Units: 60K
Revenue: \$42M *
2029

Units: 119K
Revenue: \$80M *
2030 (LATAM)

200 Units Requested



ACTIVZ



Clients & Commercial Partners



GOBIERNO DE LA
CIUDAD DE MÉXICO



Company Structure



S.A.P.I. Corporation
Mexico City, MX
Pending

Clinical Research Hub

Clinical Research & Calibration
Regional Contracts
MX Team
Mexico & LATAM Sales
Manufacturing (Optional)




Grant Opportunities
(CONAHCYT / SECTEI)
4 Previous Grants (\$3 M)


Clinical Trials - May (\$150K)
(Prepared)



C Corporation
Delaware, US
Incorporated



LTD Corporation
Ireland, EU
Pending




Principal Company (Headquarters)

Owns all subsidiaries
Holds all IP
Consolidates Global Financials
Global Contracts & Investments
US Team / Optics & Hardware Laboratory
US / Canada Sales
Manufacturing (Optional)
Royalties / Licensing / Transfer payments (Subs)



Research & Development Hub

Machine Learning & AI
Regional Contracts
EU Team
European & UK Sales
Manufacturing (Optional)



Grant Opportunities (SBIR / NIH)
\$2.4M - \$6M (R&D)

1° Submission (40%) - Apr
(Active)

2° Submission (70%) - Sep
3° Submission (90%) - Jan

Grant Opportunities
(Horizon Europe / NHS)
Previous (7/8 - \$12M EU)

Personalized Prevention 2026



Competitive Landscape









Big Tech & Pharma are limited by flexibility (Business Model, Brand, Form Factor) & Technical Challenges - **They support DeepTech Startups**

Glucose Monitoring		Universality Collective use	Affordability vs Puncture/CGM	Accuracy & Simplicity	Commercial Availability	Diversification Other Markers	Pain Invasive	Seed Round Comparison
 \$4.8 M funding	Transmittance NIR Spectroscopy PPG / Quantum Light Rotation Multi-sensor (Optical / Bioimpedance) AI Insights / Desktop / Portable Strong Signal / Multi-metric / Collective	5	5	5	4	5	5	\$3,300,000 (TBR) 2024
	 \$60 M funding Reflective NIR Spectroscopy Multi-sensor (Op./Thermal /Bioimpedance) Calibrated with Puncture Measures in Interstitial Fluid Faint Signal / Heavy Noise / Individual	3	4	5	4	3	5	\$12,500,000 2014
	 \$20 M funding Reflective mid-IR Spectroscopy Photothermal Process Portable device Measures in Interstitial Fluid Faint Signal / Heavy Noise / Uni-metric	5	3	5	4	2	5	\$5,000,000 2018
	 \$25 M funding Nanotechnology / Reverse Iontophoresis Ionized Molecule Attraction Graphene base wearable Measures in Interstitial Fluid Faint Signal / Heavy Noise	2	3	5	4	3	5	~\$2,000,000 2017
	 \$12 M funding Dielectric Spectroscopy / Radio Frequency Multi-sensor (Optical/Thermal) Semi-wearable Measures in Interstitial Fluid Faint Signal / Significant Confounders	2	3	4	4	2	5	\$5,900,000 2020
	 +\$200 M funding Smart ring for biomarker tracking Does not measure Glucose / Blood Pressure	2	2	3	5	5	5	\$2,300,000 2015

Stage of Development



2025 Product Completion

Final Iteration (3.0)
Quantum Light Rotation
Bioimpedance
Signal Reproducibility
Prototype Prod (10 u)

Fresh
NIH Grant
(\$2.4M)

ML Training
Specificity
Sensitivity



Full Patent

Research Paper

Prevention App

Production
(200 u)

Regulation (Prev)
COFEPRIS
SpO2/HR/BP

Specialized Study
(Women)

2026 Commercialization

Placement
(200 u)

Market Activation
(Women/Underserved)

Regulation (Prev)
FDA
SpO2/HR/BP

Commercial Contracts
(10,000 units)

Growth Capital
(\$10 M)

Production
(10,000 units)

Market Expansion
(US/MX)

Profitability

Cross-Sectional Study • 100K p

Second Largest Glucose
Protocol in Mexican History
Multi-Centric / Cost <\$500K



1,350 p



1,350 p



GOBIERNO DE LA
CIUDAD DE MÉXICO

3,000 p



14,000 p



80,000 p




1,350 p




500 p

Blood Pressure (Sphygmomanometer)



HR & SpO2 (Pulse Oximeter)



Blood Glucose (Capillary test)



Viit Health measures in 30 seconds what could take +17 minutes



Financial Position

* Expected for Founders after SAFE conversion & equity compensation
* Series A may not be needed (financing options / revenue acceleration)
* Forward-looking projections cannot be guaranteed

Raised to Date **\$4.8M**

R&D (2017-20)

Pre-Seed (2021-22)

Seed (2023 - 2025)

Series A (Expected Q4 2026)

\$3 M (Pre Val)

\$632 K (\$15M CAP)

\$3.3 M (\$20M CAP)

\$10 M (\$70M Exp. Val)

Current ownership (CO): 100% Founders

CO: 81.74% Founders *

7% Dilution (if needed) *

Research & Development · Calibration

Grants / Founders
CONACYT
Mexico City's Gov
Predecessor Comp

SAFE
Walton Family
Crowdfunding (407 p)
Angel Investors



Product Validation · Commercial Activation

Raised \$1.25M - SAFE
Softeq Venture Fund
Sabacica Capital
Crowdfunding (447 p)
Angel Investors



Upcoming (Potential)

Aug - **\$500K** Total Impact Capital Capital
Dec - **\$2.4M** SBIR - NIH

Production · Growth

Potential \$2.5M
Sabacica Capital
Softeq Venture Fund

Interested Leads
MaC Ventures (lead)
Glicso Partners (co-lead)



28%

12%

20%

34%

6%

Hardware &
Software Dev

Machine
Learning

Clinical Studies
& Regulatory

Operations
& Legal

Production

Open \$2.05 M - Direct Investment
\$20M Pre-Money valuation

Potential **27X ROI** 5yrs *

Financial Projections

- Revenue
- COGS
- SG&A

* forward looking projections are not guaranteed



EBITDA

-\$ 671,654

\$ 1,418,740

\$ 6,998,651

\$ 28,036,164

\$ 53,594,058

2026

2027

2028

2029

2030

Help us reshape the future of healthcare

